Research Activities of ISPOR Russia St. Petersburg Chapter
Monitoring of the Reimbursement Lists in Russia
One of the main scientific activities of ISPOR Russia St. Petersburg Chapter in 2017 was to continue the monitoring of the reimbursement lists in Russia.
In Russia the cost-effectiveness threshold is not yet introduced into the procedure of reimbursement lists revision and is not used as the criteria of inclusion or exclusion of drugs as in many other countries.
Due to the fact that in 2016 the reimbursement lists were not yet revised, ISPOR Russia St. Petersburg Chapter researchers focused on the data of the last two revisions from 2014 and 2015. They took the health economic data from the dossiers of anti-cancer drugs with ATC codes L01 and L02 submitted during that period. For each health economic evaluation they analyzed number of LYG, progression-free LYG, QALYs; incremental cost per one LYG, progression-free LYG and QALY.
The main goal was to calculate the median ICER for anti-cancer drugs included and rejected from the reimbursement and then compare it with the CE threshold in Russia. The median cost of one LYG, progression-free LYG and one QALY gained showed to be higher comparing to the willingness to pay a threshold in Russia by 1,5%, 125% and 50%, consequently. ICER/LYG did not differ between the drugs included and rejected from the reimbursement, ICER/QALY was slightly even higher in the group of included drugs compared to the group of rejected ones. This analysis was published in the Russian journal and the data is open.
The conclusion drawn from the work is that in Russia the drugs entered into the reimbursement system during the last two revisions have ICER/LYG almost equal to the threshold. (Reported by ISPOR Russia St. Petersburg Chapter)
|Alexey Kolbin, MD, PhD|
|President-Elect||Sergey Zyryanov, MD, PhD|
Alexey Kurylev, MD